Abstract

Mohamad Yosof Rezk

Visfatin is a novel adipokine showing altered plasma levels in different disorders, for example type-2 diabetes mellitus, obesity fetal growth retardation and gestational diabetes mellitus. We found that no study demonstrated the effect of visfatin on blood glucose and serum lipids in rats. Therefore, we investigated the effect of visfatin on blood glucose and serum lipids in rats. We found that visfatin produced an inhibitory effect on blood glucose level in a dose dependent manner and it caused further reduction in blood glucose level when combined with oral hypoglycemic drugs. We also found that visfatin produced a significant inhibitory effect on triglycerides, LDL and VLDL. These data are the first to show that visfatin can inhibit blood glucose in a dose dependent manner and the first to find an inhibitory effect on some serum lipids.